glp-1 weight loss effectiveness drugs leave users low on key nutrients, study finds GLP-1 Agonists In Obesity

INTRODUCTION Glucagonlike peptide1 (GLP1) receptor agonists (GLP1RAs) are an established treatment for type 2 diabetes (T2D)

Novo Nordisk and Ascendis Pharma have partnered to develop a long-acting, monthly GLP-1 drug The partnership aims to speed up the development of a long-acting, monthly GLP-1 drug

Semaglutide, while more lipophilic and longer-acting than other peptides in the class, appears to exhibit modest brain penetrance, possibly limited by its strong affinity for albumin and relatively high molecular weight [71]

GI side effects are most intense

Boost digestion

standard review is typically about 10 months